Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA)
暂无分享,去创建一个
[1] D. Goldstein,et al. The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia. , 2017, Journal of gastrointestinal oncology.
[2] Sang Kook Lee,et al. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study , 2016, Investigational New Drugs.
[3] Mingming Zhao,et al. A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma , 2015, Medical Oncology.
[4] W. Au,et al. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] R. K. Lo,et al. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1 , 2014, Annals of Hematology.
[6] Z. Chen,et al. How to manage acute promyelocytic leukemia , 2012, Leukemia.
[7] K. Lechner,et al. Cancer-Related Microangiopathic Hemolytic Anemia: Clinical and Laboratory Features in 168 Reported Cases , 2012, Medicine.
[8] L. Sehn,et al. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] J. Alonso,et al. A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic purpura , 2011, Hematology reports.
[10] L. Gordon,et al. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma , 2010, British journal of haematology.
[11] Shinichirou Takahashi. Combination therapy with arsenic trioxide for hematological malignancies. , 2010, Anti-cancer agents in medicinal chemistry.
[12] D. Valla,et al. Cancer awareness in atypical thrombotic microangiopathies. , 2009, The oncologist.
[13] Julie E. Chang,et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study , 2004, Hematological oncology.
[14] J. Berenson,et al. A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma , 2007, Clinical Cancer Research.
[15] F. Formelli,et al. Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells. , 2005, Anticancer research.
[16] Y. Honma,et al. Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-γ , 2002 .
[17] Y. Honma,et al. Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma. , 2002, Leukemia research.
[18] J. Dacie,et al. Microangiopathic Haemolytic Anaemia: The Possible Role of Vascular Lesions in Pathogenesis , 1962, British journal of haematology.